Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;386(26):2526-2528.
doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15.

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

Panke Qu  1 , Julia Faraone  1 , John P Evans  1 , Xue Zou  1 , Yi-Min Zheng  1 , Claire Carlin  1 , Joseph S Bednash  1 , Gerard Lozanski  1 , Rama K Mallampalli  1 , Linda J Saif  1 , Eugene M Oltz  1 , Peter J Mohler  1 , Richard J Gumina  1 , Shan-Lu Liu  1
Affiliations

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

Panke Qu et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Stronger Immune Escape with the BA.4/5 and BA.2.12.1 Omicron Subvariants than with BA.1 and BA.2.
Shown are neutralizing-antibody titers against virus pseudotyped with spike protein from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bearing the D614G mutation, along with the B.1.617.2 (delta) variant, the BA.1, BA.2, BA.4/5, and BA.2.12.1 subvariants of the B.1.1.529 (omicron) variant, and the BA.2 single mutants BA.2_ L452Q and BA.2_S704L in serum samples obtained from health care workers 3 to 4 weeks after they had received the second dose of messenger RNA (mRNA) vaccine (Panel A) and from health care workers after they had received the third (booster) dose of the same mRNA vaccine (Panel B). Also shown are neutralizing-antibody titers in serum samples obtained from patients with coronavirus disease 2019 (Covid-19) in the intensive care unit (ICU) during the delta wave of the Covid-19 pandemic (Panel C) and from patients who were hospitalized with Covid-19 but were not admitted to the ICU during the BA.1 wave of the pandemic (Panel D). In all panels, dots indicate individual samples, and the horizontal dashed lines indicate the limit of detection. The geometric mean values for the 50% neutralization titers (NT50) are shown at the top of the plots along with the percentage of persons with NT50 values above the limit of detection. 𝙸 bars represent 95% confidence intervals. The statistical significance of the neutralizing-antibody titers against the subvariants relative to those against the ancestral SARS-CoV-2 strain bearing the D614G mutation was determined by means of one-way repeated-measures analysis of variance with Bonferroni’s multiple testing correction. NS denotes not significant.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. COVID data tracker: variant proportions (https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
    1. National Institute for Communicable Diseases South Africa. SARS-CoV-2 genomic surveillance update: tracking SARS-CoV-2 variants (https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-co...).
    1. Zeng C, Evans JP, Pearson R, et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight 2020;5(22):e143213-e143213. - PMC - PubMed
    1. Evans JP, Zeng C, Qu P, et al. Neutralization of SARS-CoV-2 omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe 2022. April 25 (Epub ahead of print). - PMC - PubMed
    1. Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022;386:1088-1091. - PMC - PubMed

Substances

Supplementary concepts